GlassScriptPhysician profile
Richard A Stangler
NPI 1417940081
$964.02
in general payments reported to CMS, 2019-2025
17 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $60.96 · 2021: $88.00 · 2022: $166 · 2023: $96.35 · 2024: $86.56 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $173.86 | 2019-2021 | |
| Alcon Vision LLC | $140.43 | 2019-2024 | Argos |
| Regeneron Healthcare Solutions, INC. | $105.17 | 2019-2024 | Eylea Hd |
| Oyster Point Pharma, INC. | $78.11 | 2022 | |
| Abbvie INC. | $74.43 | 2023-2025 | Alphagan P, Lumigan |
| Glaukos Corporation | $72.27 | 2019-2025 | Idosetr |
| Allergan, INC. | $67.04 | 2020-2022 | |
| Sight Sciences, INC. | $54.88 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Bausch & Lomb Americas INC. | $40.88 | 2023-2024 | Xiidra, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $29.15 | 2025 | |
| Aerie Pharmaceuticals, INC. | $23.49 | 2021 | |
| Rxsight INC | $23.12 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Horizon Therapeutics Plc | $18.94 | 2021 | |
| Shire North American Group INC | $18.49 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.19 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.77 | 2022 | |
| Apellis Pharmaceuticals, INC. | $13.80 | 2023 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Stangler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.